

# Deferasirox

**Catalog No: tcsc0901**



## Available Sizes

---

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg

**Size:** 50mg

**Size:** 100mg



## Specifications

---

**CAS No:**

201530-41-8

**Formula:**

$C_{21}H_{15}N_3O_4$

**Pathway:**

Others

**Target:**

Others

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 100$  mg/mL (267.84 mM)

**Alternative Names:**

ICL 670

**Observed Molecular Weight:**


373.36

**Product Description**

Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload.

**In Vitro:** In LX-2 cells treated with 50  $\mu$ M deferasirox for 12 h,  $\alpha$ 1(I)procollagen expression is decreased by 25%, with maximal reductions (10-fold) seen following 24-120 h of treatment. Similarly,  $\alpha$ -smooth muscle actin ( $\alpha$ SMA) expression is significantly lower<sup>[1]</sup>. Deferasirox had anti-proliferative effects on HL-60 or KG-1 myeloid leukemia cell lines at a concentration as low as 5  $\mu$ M. The cytotoxicity is both dose and time dependent<sup>[2]</sup>. The viability of both EL4 cells and L1210 cells incubated with deferasirox decrease in a concentration-dependent manner<sup>[3]</sup>.

**In Vivo:** The tumor is significantly smaller in the SIO mice treated with deferasirox compared with control. Mice treated with DFX showed longer survival than the other groups. Deferasirox has a survival benefit for SIO leukemia murine model in terms of iron chelation and antileukemic therapy<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!